🔎 Trials Near Me

Gara Jalqabaatti › Dukkana Bladder › Oklahoma

Qorannoo klinikaalii Dukkana Bladder Oklahoma keessatti

Qorannoo 12 Dukkana Bladder f Oklahoma keessatti hirmaatuu jiru.

Magaalota Oklahoma keessatti

Takkalaa qorannoo (Ingiliffa)

The Vanguard Study: Testing a New Way to Screen for Cancer

  • University of Oklahoma Health Sciences Center, Oklahoma City
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
Umuriin 45 hanga 75 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06995898

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

  • University of Oklahoma Health Sciences Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06770582

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

  • University of Oklahoma Health Sciences Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT07000084

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mercy Hospital Oklahoma City, Oklahoma City
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 40 hanga 75 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT05334069

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

  • University of Oklahoma Health Sciences Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT07061964

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • Cancer Centers of Southwest Oklahoma Research, Lawton
  • University of Oklahoma Health Sciences Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT03866382

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

  • University of Oklahoma - Health Sciences Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Hag-2026 · NCT05614739

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

  • University of Oklahoma Health Sciences Center, Oklahoma City
  • Mercy Hospital Oklahoma City, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Hag-2026 · NCT07097142

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  • OU Health Stephenson Cancer Center, Oklahoma City
  • OU Medical Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ado-2026 · NCT04879329

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • OU Health University of Oklahoma Medical Center, Oklahoma City
  • Stephenson Cancer Center (chemo location), Oklahoma City
  • University of Oklahoma Health Science Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 06-Ado-2026 · NCT04389632

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

  • Mercy Hospital - OKC, Oklahoma City
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Wax-2026 · NCT07327489

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Tulsa
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 28-Onk-2025 · NCT03452774

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.